KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Q3 2025 value amounting to $40.6 million.

  • Amneal Pharmaceuticals' Other Accumulated Expenses rose 3451.51% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 3451.51%. This contributed to the annual value of $31.8 million for FY2024, which is 5875.33% down from last year.
  • Amneal Pharmaceuticals' Other Accumulated Expenses amounted to $40.6 million in Q3 2025, which was up 3451.51% from $41.5 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $275.3 million for Q2 2022, and its period low was $30.1 million during Q1 2024.
  • In the last 5 years, Amneal Pharmaceuticals' Other Accumulated Expenses had a median value of $58.0 million in 2021 and averaged $78.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 8531.55% in 2022, then crashed by 7203.04% in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Other Accumulated Expenses stood at $58.0 million in 2021, then skyrocketed by 85.32% to $107.5 million in 2022, then fell by 28.37% to $77.0 million in 2023, then plummeted by 58.75% to $31.8 million in 2024, then grew by 27.85% to $40.6 million in 2025.
  • Its last three reported values are $40.6 million in Q3 2025, $41.5 million for Q2 2025, and $43.5 million during Q1 2025.